The vacancy of the University of Oxford and AstraZeneca against the covid-19 has been met with retaliation from some collectives in Europe, that the screen is less effective, but with the available dates no better or less formal formulas can be used, in addition to all the approvals son security and efficiencies.
As indicated by Efe the investigator in the Department of Infectious Diseases of King’s College London, José Manuel Jiménez Guardeño, for whom “the most important message that can be given is that the best vaccine is the first to be administered. to be elegant “.
The virologist Santiago Elena, of the Institute of Integrative Biology of Systems Systems of the CSIC, was informed of the passage of the 21st World Health Organization (WHO) to declare that “there is no such thing as a difference” between Pfizer preparations, Modern y Oxford / AstraZeneca.
The minimum age is 18 and there is no maximum limit for recipients, “the three are equal to good” for women who are embarrassed, “there are no problems for lactating mothers, they can be” with the same tranquility “in people with the compromised immune system , que padezcan VIH o que ya hayan tenido covid-19, enumera.
Without embarrassment, in European cities there are voices that do not want the Anglo-Swedish company. Some health workers and other German collectives have shown their reluctance and, in Berlin, where freedom to speak, the majority prefers the preparation of BioNTech / Pfizer or Modern.
In Oostenryk, medical clinics of the AKH University Clinic in Vienna have sent me an “online” petition to present the evacuation plan and receipt of the Pfizer, which is considered more effective. Some similar ones have been added in other regions of the country such as Salzburg or Estiria.
The main motive for this performance in various landscapes is the superstructure minor efficiency. The Pfizer and Moderna vacancies have 95% and the Oxford / Astrazeneca range up to 60-70% when the doses are applied.
“Whereas these results can be seen as the first ones are much more effective. Without embarrassment, it is not clear, because these results are not very comparable. The reason is that each clinical trial is different and uses groups of oaths and distinct criteria”, indica Jiménez.
It is now clear that the second dose of the AstraZeneca vaccine will increase, as a result, as a result, “it will be ready to make comparisons” and it will hope to see the effects of the “real life” vaccination.
Elena explains that she has a 70% protection “does not want anyone to think that the 30 recipients will be disfigured”.
The vacancies are a complex theme in which many factors are involved, its “complicated dates” that, many times, “those that are meted out to those who learn from the times, as intended to explain in a short story of 30 seconds” .
Another argument is that the preparation of the British development series is less effective than the South African variant, hecho, this country has decided not to apply at the moment, but it is said – said Jiménez- of studies “will be very preliminary and with a very strong model.
In the case where it is said that “protection is limited to some of the new variants, simply because updating the vacancies, this is a very simple process and quick to implement”.
In addition, in some European countries this vacancy is not recommended for Mayors from 65 to 55 years, depending on the place. Elena says she has to say that in those cases she has not had enough people for more than 55 years, “so there was a defect in the design of the model”, which -after Jiménez- “does not have enough data currently to evaluate her efficiency “.
When applied, says Elena, “always is the principle of maximum precaution” and as there are not enough major people in the same country as the precaution of vacancies with AstraZeneca, there are others available.
También hay quien muster sus reticencias porque la vacuna de la Oxford Universidad Oxaria daría reactions leves más frecentes tras su administración, pero, según Jiménez, son “muy parecidas” al resto.
If we take the first dose, “you can see that the effects of the Oxford / AstraZeneca vaccine can be more frequent and more intense quizzes, but you can use a viral vector in the ARN message box”, which is Pfizer technology and Modern “.
Without embarrassment, Jiménez says that, as he has seen, the second dose of Pfizer or Modern “will have more intense effects than the first one, in the case of Oxford / AstraZeneca, more live.
In addition, Elena’s latest has “including a sale” for people with a history of allergies or anaphylactic outbreaks, since they do not contain the adjuvants that are other than those based on ARN’s message, which “can cause.
The AstraZeneca also has “the promise that transport and logistics are definitely simpler” can -agre- be preserved in a few degrees, not the -20 that require the Pfizer Modern or -80.
Based on “objective criteria” has no justification “to recover the AstraZeneca vacancy, says Elena, who could have been more involved with the sociological part of seeing the company has had difficulties in filling in the gap to be reached with the European Union.
AstraZeneca’s delegate, Pascal Soriot, points out in Brussels that the company hopes to “break the day” with its contractual agreements with the European Union on holiday vacations in the second quarter of this year.
Both experts say that all vacancies are “safe and functional” and that there is no time to breathe. When we take the flu, Jiménez recalls, “we do not know how to get it, if it is based on inactive viruses or subunits, which use seizures, its brand or its effects and, without embarrassment, its benefits are more obvious “.
Elena points out that we have a public health issue and it is important that there is a “protection of the most large group and that it is done with all vacancies”.